En 2024, toujours rien à attendre de la visite médicale des firmes pharmaceutiques1
Les tribunes de la santé · 2024
DOI: 10.1684/seve1.2024.11 ↗Kurz gefasst
Fachartikel in der Zeitschrift Les tribunes de la santé, 2024.
Abstract (Originalsprache)
France’s Haute Autorité de Santé (HAS) (National Authority for Health) has published a report on the interactions between healthcare professionals and pharmaceutical firms, particularly via pharmaceutical detailing. HAS notes that professionals’ exposure to these interactions is early, ubiquitous, and global. According to the methodical summary of studies published between 2004 and 2018 by HAS, the information conveyed by pharmaceutical detailing is of poor quality; and healthcare professionals lack the critical thinking and training to discern its influences on their practice. Various regulatory measures have been introduced in some countries to limit the impact on healthcare. So far, they have been inconclusive. The most effective way of limiting the influence of the pharmaceutical sales force on drug prescribing and dispensing is still to avoid receiving sales reps.
Zitieren
APA
(2024). En 2024, toujours rien à attendre de la visite médicale des firmes pharmaceutiques1. Les tribunes de la santé. https://doi.org/10.1684/seve1.2024.11
Vancouver
En 2024, toujours rien à attendre de la visite médicale des firmes pharmaceutiques1. Les tribunes de la santé. 2024. doi:10.1684/seve1.2024.11
BibTeX
@article{euvimed2024,
title = {En 2024, toujours rien à attendre de la visite médicale des firmes pharmaceutiques1},
journal = {Les tribunes de la santé},
year = {2024},
doi = {10.1684/seve1.2024.11}
}
EUVIMED